No development-stage or early clinical trial-stage biotech has revenues. When you see people screaming about no revenues in an early-stage biotech like AVXL, either they don't understand how these companies develop, or they are trying to scare investors into selling.
I currently have NO POSITION in AVXL because I have doubts about the way the company does its business and runs its clinical trials.
However, people should do their own due diligence and not be scared by bashers.
(2)
(0)
Anavex Life Sciences Corp. (AVXL) Stock Research Links